Biodesix (NASDAQ:BDSX – Get Free Report) and XWELL (NASDAQ:XWEL – Get Free Report) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their valuation, profitability, earnings, risk, analyst recommendations, institutional ownership and dividends.
Profitability
This table compares Biodesix and XWELL’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Biodesix | -53.66% | -269.67% | -43.94% |
| XWELL | -63.18% | -265.41% | -72.67% |
Analyst Recommendations
This is a breakdown of current ratings and price targets for Biodesix and XWELL, as reported by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Biodesix | 1 | 1 | 4 | 0 | 2.50 |
| XWELL | 1 | 0 | 0 | 0 | 1.00 |
Valuation & Earnings
This table compares Biodesix and XWELL”s revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Biodesix | $71.32 million | 0.69 | -$42.93 million | ($5.80) | -1.16 |
| XWELL | $33.90 million | 0.17 | -$16.85 million | ($4.10) | -0.24 |
XWELL has lower revenue, but higher earnings than Biodesix. Biodesix is trading at a lower price-to-earnings ratio than XWELL, indicating that it is currently the more affordable of the two stocks.
Institutional and Insider Ownership
21.0% of Biodesix shares are owned by institutional investors. Comparatively, 8.7% of XWELL shares are owned by institutional investors. 30.1% of Biodesix shares are owned by insiders. Comparatively, 13.9% of XWELL shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.
Risk and Volatility
Biodesix has a beta of 0.98, meaning that its share price is 2% less volatile than the S&P 500. Comparatively, XWELL has a beta of 1.06, meaning that its share price is 6% more volatile than the S&P 500.
Summary
Biodesix beats XWELL on 9 of the 14 factors compared between the two stocks.
About Biodesix
Biodesix, Inc. operates as a data-driven diagnostic solutions company in the United States. The company offers blood-based lung tests, including Nodify XL2 and Nodify CDT tests, together marketed as part of Nodify Lung Nodule Risk Assessment testing strategy, to assess the risk of lung cancer and help in identifying the appropriate treatment pathway and help physicians in reclassifying risk of malignancy in patients with suspicious lung nodules. It also provides GeneStrat ddPCR and NGS, and VeriStrat tests, which are used in the diagnosis of lung cancer to measure the presence of mutations in the tumor and the state of the patient's immune system to establish the patient's prognosis and help guide treatment decisions. In addition, the company, through its partnership with Bio-Rad Laboratories, Inc., provides Bio-Rad SARS-CoV-2 ddPCR, a COVID-19 Test under Biodesix WorkSafe testing program; and Platelia SARS-CoV-2 Total Ab test, an antibody test for detecting a B-cell immune response to SARS-CoV-2 that indicate recent or prior infection. Further, it offers diagnostic and clinical research, as well as clinical trial testing services to biopharmaceutical companies; and discovers, develops, and commercializes companion diagnostics. The company was formerly known as Elston Technologies, Inc. and as changed to Biodesix, Inc. in 2006. Biodesix, Inc. was incorporated in 2005 and is headquartered in Louisville, Colorado.
About XWELL
XWELL, Inc. provides health and wellness services in airport and off airport marketplaces in the United States and internationally. It operates in four segments: XpresSpa, XpresTest, Naples Wax Center, and Treat. The XpresSpa segment traveler's spa services, including massage, nail, and skin care services, as well as spa and travel products. The XpresTest segment offers diagnostic COVID-19 tests at XpresCheck Wellness Centers in airports, to airport employees and to the traveling public but has transitioned to the CDC's bio-surveillance program; and provides marketing support through HyperPointe business to various health and health-related channels. The Napple Wax Center segment offers skincare and cometic products, as well as face and body waxing services. The Treat segment provides access to wellness services for travelers at on-site centers, consisting of self-guided yoga, meditation, and low impact weight exercises programs. The company offers its services through stores, kiosks, and online. The company was formerly known as XpresSpa Group, Inc. and changed its name to XWELL, Inc. in October 2022. XWELL, Inc. is based in New York, New York.
Receive News & Ratings for Biodesix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Biodesix and related companies with MarketBeat.com's FREE daily email newsletter.
